NASDAQ:NXTM - NxStage Medical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$27.64 +0.25 (+0.91 %)
(As of 07/22/2018 01:20 AM ET)
Previous Close$27.64
Today's Range$27.38 - $27.92
52-Week Range$22.70 - $29.93
Volume276,758 shs
Average Volume391,954 shs
Market Capitalization$1.82 billion
P/E Ratio-125.64
Dividend YieldN/A
Beta-0.07
NxStage Medical logoNxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts.

Receive NXTM News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:NXTM
CUSIP67072V10
Phone978-687-4700

Debt

Debt-to-Equity RatioN/A
Current Ratio3.51
Quick Ratio2.39

Price-To-Earnings

Trailing P/E Ratio-125.64
Forward P/E Ratio-2,764.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$393.94 million
Price / Sales4.67
Cash Flow$0.2937 per share
Price / Cash94.11
Book Value$3.22 per share
Price / Book8.58

Profitability

EPS (Most Recent Fiscal Year)($0.22)
Net Income$-14,470,000.00
Net Margins-3.65%
Return on Equity-6.83%
Return on Assets-4.49%

Miscellaneous

Employees3,800
Outstanding Shares66,500,000
Market Cap$1,821.35

NxStage Medical (NASDAQ:NXTM) Frequently Asked Questions

What is NxStage Medical's stock symbol?

NxStage Medical trades on the NASDAQ under the ticker symbol "NXTM."

How were NxStage Medical's earnings last quarter?

NxStage Medical, Inc. (NASDAQ:NXTM) issued its quarterly earnings results on Thursday, May, 10th. The medical device company reported ($0.02) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.02 by $0.04. The medical device company had revenue of $107.30 million for the quarter, compared to analyst estimates of $106.95 million. NxStage Medical had a negative return on equity of 6.83% and a negative net margin of 3.65%. View NxStage Medical's Earnings History.

What price target have analysts set for NXTM?

8 brokerages have issued 1 year target prices for NxStage Medical's shares. Their predictions range from $30.00 to $30.00. On average, they anticipate NxStage Medical's stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 8.5% from the stock's current price. View Analyst Ratings for NxStage Medical.

What is the consensus analysts' recommendation for NxStage Medical?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NxStage Medical in the last year. There are currently 8 hold ratings for the stock, resulting in a consensus recommendation of "Hold."

Who are some of NxStage Medical's key competitors?

Who are NxStage Medical's key executives?

NxStage Medical's management team includes the folowing people:
  • Mr. Jeffrey H. Burbank, Founder, CEO & Director (Age 55)
  • Mr. Joseph E. Turk Jr., Pres (Age 50)
  • Mr. Matthew W. Towse, Sr. VP, CFO & Treasurer (Age 55)
  • Ms. Winifred L. Swan, Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Dr. Allan J. Collins, Head of Scientific Advisory Board & Chief Medical Officer

Has NxStage Medical been receiving favorable news coverage?

News stories about NXTM stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NxStage Medical earned a daily sentiment score of 0.23 on Accern's scale. They also assigned press coverage about the medical device company an impact score of 46.51 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are NxStage Medical's major shareholders?

NxStage Medical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.63%), Tokio Marine Asset Management Co. Ltd. (0.06%) and Steward Partners Investment Advisory LLC (0.01%). Company insiders that own NxStage Medical stock include Craig W Moore, Daniel A Giannini, Jeffrey H Burbank, Joseph E Turk Jr, Matthew W Towse, Robert S Brown and Winifred L Swan. View Institutional Ownership Trends for NxStage Medical.

Which major investors are selling NxStage Medical stock?

NXTM stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold NxStage Medical company stock in the last year include Joseph E Turk Jr, Matthew W Towse and Winifred L Swan. View Insider Buying and Selling for NxStage Medical.

Which major investors are buying NxStage Medical stock?

NXTM stock was bought by a variety of institutional investors in the last quarter, including Tokio Marine Asset Management Co. Ltd. and Steward Partners Investment Advisory LLC. View Insider Buying and Selling for NxStage Medical.

How do I buy shares of NxStage Medical?

Shares of NXTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NxStage Medical's stock price today?

One share of NXTM stock can currently be purchased for approximately $27.64.

How big of a company is NxStage Medical?

NxStage Medical has a market capitalization of $1.82 billion and generates $393.94 million in revenue each year. The medical device company earns $-14,470,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. NxStage Medical employs 3,800 workers across the globe.

How can I contact NxStage Medical?

NxStage Medical's mailing address is 350 MERRIMACK STREET, LAWRENCE MA, 01843. The medical device company can be reached via phone at 978-687-4700 or via email at [email protected]


MarketBeat Community Rating for NxStage Medical (NASDAQ NXTM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  269 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  494
MarketBeat's community ratings are surveys of what our community members think about NxStage Medical and other stocks. Vote "Outperform" if you believe NXTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.